References
- Souhami R, Tobias J, editors. Breast cancer. In: Cancer and its management. Oxford: Blackwell Science; 1998. pp. 216–34
- Paterson AHS. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer 2000;88:3038–46
- The Breast Specialty Group of the British Association of Surgical Oncology. British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom. Eur J Surg Oncol 1999;25:3–23
- Lacerna L, Hohneker J. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumours. Seminars in Oncology 2003;30(5 Suppl 16):150–60
- Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. The Cancer Journal 2001;7(5):377–87
- Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technology Assessment 2004;8(4)
- Pavlakis N, Stockler M. Bisphosphonates for breast cancer (Cochrane review). The Cochrane Library, vol. 4. Chichester, UK: John Wiley & Sons, Ltd; 2003
- Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [Myeloma Aredia Study Group]. NEJM 1996;334(8):488–93
- Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [Myeloma Aredia Study Group]. J Clin Oncol 1998;16(2):593–602
- Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate [Protocol 19 Aredia Breast Cancer Study Group]. J Clin Oncol 1998;16(6):2038–44
- Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases [Protocol 19 Aredia Breast Cancer Study Group]. NEJM 1996;335(24):1785–91
- Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is an effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88(5):1082–90
- NHS Executive Reference Costs 2003. Leeds: Department of Health 2003
- BNF (British National Formulary). London: BMA and Royal Pharmaceutical Society of Great Britain, 2004
- Datamonitor. Treatment algorithms 2001: Breast cancer. Reference Code: DMHC1683. 2001. Datamonitor, London
- Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia; WB Saunders Co.; 1980. pp. 228–65
- Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003;98(8): 1735–43
- Romanus D, Iscoe N, DeAngelis C, et al. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. Supportive Care in Cancer 2004 [published on line]
- DesHarnais Castel L, Bajwa K, Markle JP, et al. A microcosting of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care in Cancer 2001;9:545–51